Summit Plc (SMMT)
Summit Plc - Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026
Summit Plc - Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026
📊 **NEUTRAL** • Medium confidence analysis (70%) • Weak signals • Minimal impact expected **Sentiment:** Neutral (50%) **Content type:** General